Humulin 70-30 Articles
Eli Lilly views additional $180 million investment to expand insulin making in Indianapolis
2 April 2013
Ground-breaking on new Novo Nordisk plant in Russia
17 April 2012
Pfizer and Biocon cancel biosimilars deal
14 March 2012
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
3 March 2010
While weakening of Mexico’s peso is causing problems, generics will fuel pharma market growth
25 February 2010
US FDA warns Lilly on insulin API manufacturing violations and Roche and Abbott over HIV combo drug concerns
24 February 2010
Vaccine for diabetes possible this decade, creating a potential $2.4 billion market by 2020, says Report
22 February 2010
Denmark’s Novo Nordisk debuts Victoza in the USA, aiming for $1 billion global sales by 2015
17 February 2010
Sanofi-Aventis 2009 EPS leaps 18% but slows in 4th quarter; in line with expectations
10 February 2010
UK/Czech scientists shed light on insulin activity
9 February 2010
German pharma developing drugs against 31 forms of cancer
8 February 2010
FDA approves Novo Nordisk’s new type 2 diabetes drug Victoza
26 January 2010
Diabetes and pre-diabetes in USA accounted for $218 billion in costs in 2007, study shows
14 January 2010
Pfizer makes another move into generics in deal with Strides Arcolab; enters into discovery accord with Ensemble
7 January 2010
Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid
22 December 2009
Roche/Ipsen’s taspoglutide meets Ph III primary endpoints against Lantus and placebo in patients with high BMI
18 December 2009
Pharma market in Denmark expected to grow at 8% pa through 2014
15 December 2009
Scottish Medical Consortium backs use of Novo Nordisk’s Victoza for type 2 diabetics
9 December 2009
Sanofi-Aventis to reinforce its presence in Russia via the ”Pharmpolis Project;” Multaq approved by EC
30 November 2009
US HHS Secretary Sebelius highlights problems for diabetics and Health Insurance Reform
12 November 2009
Novo Nordisk’s third-quarter 2009 profit rises 3%
2 November 2009
Sanofi-Aventis says strong swine flu vaccine sales in 4th quarter will drive higher earnings
30 October 2009
Ipsen launch’s Dysport in USA, updates on taspoglutide
29 October 2009
Eli Lilly 3rd quarter 2009 beats forecasts, raises guidance
22 October 2009
Wellstat could earn $350 million from Sanofi-Aventis deal for novel type 2 diabetes age
21 October 2009
Latest diabetes figures paint grim global picture
21 October 2009
Biosimilar insulins and analogs set to erode $6.1 billion in brand sales in the USA and Europe by 2018
15 October 2009
Sanofi-Aventis launches major insulin research program; updates on rimonabant court case
30 September 2009
Ipsen reveals positive findings with rhGH and Increlex
16 September 2009
Global biosimilars product market worth $19.4 billion by 2014
2 September 2009
Global diabetes market set to grow to $44.7 billion in 2015, fuelled by improved treatments
19 August 2009
Novo Nordisk initiates new Levemir study
5 June 2009
Novo Nordisk's Levemir lowers ave blood sugar
14 May 2009
Novo Nordisk
7 May 2009
Lilly's 1st-qtr profit jumps 23.6% to $1.31B
29 April 2009
Japan stock market week to April 27, 2009
28 April 2009
Sanofi sees more China opportunities
24 April 2009
Sanofi invests $90M in Lantus plant in China
22 April 2009
Sanofi launches Apidra SoloSTAR in USA
21 April 2009
Takeda drops Ph II diabetes candidate
21 April 2009
Diabetes sales weaken with economy
20 April 2009
Record sales for Sanofi Japan, says president
14 April 2009
Liver therapy may cure diabetes, says study
30 March 2009
ADA/AACE play down new trial results
30 March 2009
Additional Actos indication for Takeda
30 March 2009
Plant-derived insulin passes first human study
30 March 2009
Drivers of Europe's biosimilars market
30 March 2009
More strong results for Novo's liraglutide
27 March 2009
Nordisk's liraglutide reduces HbA1c
23 March 2009
Oral-lyn trial on track for successful early finish
16 March 2009
Tolerx expands Ph III otelixizumab trial in Europe
16 March 2009
MannKind buys Pfizer insulin facility
16 March 2009
Virus in pancreas linked to diabetes type 1
16 March 2009
Sanofi's Apidra SoloSTAR cleared in the USA
9 March 2009
Corlux plus Risperdal results in less abdominal fat
2 March 2009
Explosion of diabetes cases in UK
2 March 2009
Sanofi launches Apidra in Canada
2 March 2009
Japan stock market week to Feb 9, 2009
16 February 2009
PrandoiMet launched in USA
16 February 2009
Novo Nordisk profits up 13% on insulin sales
9 February 2009
Lilly swings to loss on ImClone acquisition
9 February 2009
Low-carb diet burns more excess liver fat
26 January 2009
Generex' insulin mouth spray approved in Lebanon
19 January 2009
Review suggests vit D delays diabetes onset
19 January 2009
Japan stock market week to Jan 12, 2009
19 January 2009
Polish diabetes group "devastated" over reimbursement list
19 January 2009
Japan stock market week to Jan 5, 2009
12 January 2009
Report says Novo and US Merck will top 2014 metabolism market
12 January 2009
Americans stretching Rxs to save money
12 January 2009
SemBioSys gets $2.5M from MannKind for plant-based insulin
12 January 2009
MannKind reports rapid insulin trial success
12 January 2009
Xoma to initiate Ph II trial of diabetes MAb
22 December 2008
Novo partners with Merrion over Insulin analogs
15 December 2008
Dosing begins in Ph Ib trial of Genaera's trodusquemine
8 December 2008
FDA updates on delay for Nordisk's liraglutide
24 November 2008
Novo to invest $400M in China insulin plant
17 November 2008
Sirtris drug blocks weight gain in mice
10 November 2008
SmartCells enters $1M partnership with JDRF
10 November 2008
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
